A phase I study of pentosan polysulfate sodium in patients with advanced malignancies

Annals of Oncology

Volumn 7, Issue 9, 1996, Pages 939-944

  Lush, R M ^a   Figg, W D ^a   Pluda, J M ^a   Bitton, R ^a,c   Headlee, D ^a   Kohler, D ^b   Reed, E ^a   Sartor, O ^a,d   Cooper, M R ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

aPTT; cancer; growth factors; heparan sulfate; heparinoid; pentosan; phase I

Indexed keywords

PENTOSAN POLYSULFATE;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOPLASTIN TIME;

EID: 0030451604     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010797     Document Type: Article

References (32)

1. Bergqvist D, Efsing H, Hallbook T, Lindblad B. Prevention of post-operative thromboembolic complications: A prospective comparison between dextran 70, dihydroergotamine heparin and sulfated polysaccharide. Acta Chir Scand 1980; 146: 559-68.
2. Bergqvist D, Ljungner H. A comparative study of dextran 70 and a sulfated polysaccharide in the prevention of post-operative thromboembolic complications. Br J Surg 1981; 68: 449-51.
3. Joffe S. Drug prevention of postoperative deep vein thrombosis: A comparative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg 1976; 111: 37-40.
4. Scully M, Kakker V. Identification of heparin cofactor II as the principal plasma co-factor for the antithrombin activity of pentosan polysulfate (SP54). Thromb Res 1984; 36: 187-94.
5. Klein-Soyer C, Beretz A, Cazenave JP et al. Sulfated polysaccharides modulate effects of acidic and basic fibroblast growth factors on repair of injured confluent human vascular endothelium. Arterioscler 1989; 9: 147-53.
6. Pienta JK, Murphy BC, Isaacs WB et al. Effect of pentosan, a novel cancer chemotherapeutic ageant, on prostate cancer cell growth and motility. The Prostate 1992; 20: 233-41.
7. Nguyen N, Lehr JE, Pienta KJ. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res 1993; 13: 2143-8.
8. Wellstein A, Zugmaier G, Califano JA et al. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 1991; 83: 716-20.
9. Herbert JM, Cottineau M, Driot F et al. Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro. Biochem Pharmacol 1988; 37: 4281-8.
10. Zugmaier G, Lippman ME, Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 1992; 84: 1716-24.
11. Pluda JM, Shay LE, Foli A et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993; 85: 1585-92.
12. Gaffhey PJ, Marsh NA. The effect of pentosan polysulphate (SP54) on the human fibrinolytic system. Folia Haematol 1986; 113: 262-71.
13. Barrowcliffe TW, Gray E, Merton RE et al. Anticoagulant activities of pentosan polysulphate (hemoclar) due to release of hepatic triglyceride lipase (HTGL). Thromb Haemost 1986; 56: 202-6.
14. Soria C, Soria J, Ryckewaert JJ et al. Anticoagulant activities of a pentosane polysulfate: Comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19: 455-63.
15. MacGregor IR, Dawes J, Pepper DS et al. Metabolism of sodium pentosan polysulfate as measured by a new competitive binding assay for sulfated polysaccharides-comparison with effects upon anticoagulant activity, lipolysis, and platelet-granule protein. Thromb Haemost 1985; 53: 411-4.
16. Ofosu F, Blajchnan M, Modi GJ et al. The importance of thrombin inhibition for the expression of the anticoagulant activity of heparin, dermatan sulfate, low molecular weight heparin, and pentosan polysulfate. Br J Haematol 1985; 60: 695-704.
17. Ofosu F, Fernandez F, Anvari N et al. Further studies on the mechanisms for the anti-thrombotic effects of sulfated polysaccharides in rabbits. Thromb Haemost 1988; 60: 188-92.
18. Bergqvist D, Falke P, Jaroszewski H, Lamme S. Comparison between heparin and a heparin analogue (sodium pentosan polysulphate) in the initial treatment of deep vein thrombosis. VASA 1986; 15: 77-80.
19. deProst D, Guerot C, Karsenty F. Pentosan polysulfate: The effect on hemostasis of a continuous 3 day infusion. Clin Pharmacol Ther 1985; 38:171-82.
20. Sie P, Albarede J, Robert M et al. Tolerance and biologic activity of pentosan polysulfate after intramuscular or subcutaneous administration for 10 days in human volunteers. Thromb Haemost 1986; 55: 86-9.
21. Fischer A-M, Merton RE, Marsh NA et al. A comparison of pentosan polysulphate and heparin II: Effects of subcutaneous injection. Thromb Haemost 1982; 47: 109-13.
22. Swain S, Wellstein A, Parker B et al. Heparin-binding growth factor blockade with pentosan polysulfate. Ann NY Acad Sci 1993; 698: 63-70.
23. Vinazzer H, Stemberger A, Haas S, Blumel G. Influence of heparin of different heparin fractions and of a low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-52.
24. Vinazzer H. Clinical studies on the fibrinolytic effect of pentosan polysulfate. Folia Haematol, Leipzig (Letter) 1986; 113: 272-7.
25. Wittes RE. Appendix A: Grading of toxicity. In Wittes RE (ed): Manual of Oncologic Therapeutics 1991/1992. Philadelphia: J.B. Lippincott; 445-8.
26. Swain S, Parker B, Wellstein A et al. Phase I trial of pentosan polysulfate. Invest New Drugs 1995; 13: 55-62.
27. Follea G, Hamandjian I, Trzeciak M-C et al. Pentosane polysulphate associated thrombocytopenia. Thromb Res 1986; 42: 413-8.
28. Tannenbaum S, Alms L, Goad K et al. Pentosan induces thrombocytopenia and platelet dysfunction during continuous i.v. infusion. Blood 1991 ; 575 (Abstr).
29. Goad KE, Home MK, Gralnick HR. Pentosan-induced thrombocytopenia: Support for an im complex mechanism. Br J Haematol 1994; 88(4): 803-8.
30. Cadroy Y, Dol F, Caranobe C et al. Pharmacokinetics of 1251-labeled pentosan polysaccharid polysulfate in the rabbit. Thromb Res 1987; 48: 373-8.
31. Peters M, Witvrouw M, DeClercq E, Ruf B. Pharmacokinetics of intravenous pentosan polysulphate (HOE/BAY 946) in HIV-positive patients. AIDS 1991; 5: 1534-5.
32. MacGregor I, Dawes J, Paton L et al. Metabolism of pentosan polysulfate in man-catabolism of iodinated derivatives. Thromb Haemost 1984; 51: 321-5.